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Leukotriene E4 is a full functional 
agonist for human cysteinyl 
leukotriene type 1 receptor-
dependent gene expression
Holly R. Foster1,2,*, Elisabeth Fuerst1,2,*, William Branchett1,2, Tak H. Lee1,2,†, 
David J. Cousins1,2,3 & Grzegorz Woszczek1,2
Leukotriene E4 (LTE4) the most stable of the cysteinyl leukotrienes (cysLTs) binds poorly to classical 
type 1 (CysLT1) and 2 (CysLT2) receptors although it induces potent responses in human airways in vivo, 
such as bronchoconstriction, airway hyperresponsiveness and inflammatory cell influx suggesting the 
presence of a novel receptor that preferentially responds to LTE4. To identify such a receptor two human 
mast cell lines, LAD2 and LUVA, were selected that differentially responded to LTE4 when analysed by 
intracellular signalling and gene expression. Comparative transcriptome analysis and recombinant gene 
overexpression experiments revealed CysLT1 as a receptor responsible for potent LTE4-induced response 
in LAD2 but not in LUVA cells, an observation confirmed further by gene knockdown and selective 
inhibitors. Lentiviral overexpression of CysLT1 in LUVA cells augmented intracellular calcium signalling 
induced by LTE4 but did not restore full agonist responses at the gene expression level. Our data support 
a model where both an increased expression of Gαq-coupled CysLT1, and sustained intracellular calcium 
mobilisation and extracellular signal-regulated kinase (Erk) activation, are required for LTE4-mediated 
regulation of gene expression in human cells. Our study shows for the first time that CysLT1 expression is 
critically important for responsiveness to LTE4 within a human cell system.
Cysteinyl leukotrienes (cysLTs) (LTC4, LTD4 and LTE4) play pivotal roles in cell proliferation, differentiation, 
migration and regulation of immune responses implicated in a wide variety of disorders, including asthma, 
allergy, atherosclerosis and cancer1. CysLTs are products of the 5-lipoxygenase (5-LO) pathway. 5-LO converts 
arachidonic acid to an unstable intermediate LTA4, which is then conjugated to reduced glutathione by leukot-
riene C4 synthase to form LTC4. After transport to the extracellular space LTC4 is converted to LTD4 and then 
to the terminal product LTE4, the most abundant cysLT in biological fluids. The biological actions of cysLTs are 
mediated by 2 currently identified G-protein coupled receptors (GPCR): cysLT type 1 (CysLT1) and 2 (CysLT2) 
receptors. They differ in binding affinities for different cysLTs. CysLT1 is recognized as a high-affinity receptor 
for LTD4, whereas CysLT2 binds LTC4 and LTD4 with similar affinity. LTE4, the most stable of the cysLTs, binds 
poorly to the classical CysLT1 and CysLT2 and is also much less potent than LTC4 and LTD4 in inducing cellular 
responses in vitro, showing a partial agonistic activity2–5. However in vivo, it is LTE4 that has shown to be the most 
potent cysLT in eliciting influx of eosinophils and basophils into bronchial mucosa of asthmatic subjects and in 
enhancing airway responsiveness to histamine and increasing vascular permeability, suggesting the existence of 
one or more leukotriene receptors that have not been identified to date6–10. The potential presence of such a recep-
tor has been demonstrated in CysLT1/CysLT2 double knock-out mice11 but human data are lacking.
The observations that asthmatic airways respond with enhanced bronchoconstriction to inhaled cysLTs, 
especially to LTE4 in comparison with normal subjects10 and that infiltration of airways by mast cells is asso-
ciated with disordered airway function in asthma12 suggest that mast cells could be a potential target cell type 
expressing a putative receptor preferentially responding to LTE4. In fact, the possible existence of such a novel, 
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LTE4-activated receptor has been suggested in human mast cells13. In this study LTE4 has been shown to be 
the most potent of cysLTs in inducing cell proliferation and activation of gene expression in human primary 
mast cells and LAD2 human mast cell line. LTE4-mediated activities were resistant to knockdown of CysLT1 
and CysLT2 but were dependent on PPAR-γ signalling. Another study has suggested that the P2Y12 receptor is 
required for LTE4-mediated responses14 but these observations have not been confirmed15.
In order to identify such a receptor responding to LTE4 we studied human mast cells and used transcriptome 
profiling by microarrays, recombinant GPCR overexpression models and methods analysing GPCR signalling. 
We characterize LTE4 as a fully functional agonist activating human CysLT1 and show for the first time that 
CysLT1 expression is critically important for responsiveness to LTE4 within a human cell system.
Results
LTE4 signals differently in LAD2 and LUVA cells. LTE4 has been shown to induce potent responses in 
LAD2 cells13 offering a model for identification of the elusive receptor responsible for LTE4 signalling. In order to 
compare responses between LTD4 and LTE4 microarray analysis of LAD2 cells stimulated with either vehicle con-
trol, LTD4 or LTE4 was carried out in the presence of L-cysteine (3 mmol/L) to inhibit dipeptidase enzyme respon-
sible for converting LTD4 to LTE416. Both leukotrienes significantly regulated expression of 64 genes including 
many chemokines, growth and transcription factors (Fig. 1A and supplementary Table 1). LTE4 was more potent 
in up and down regulation of gene expression than LTD4 for the majority of analysed genes, providing strong 
evidence for a robust LTE4 response in LAD2 cells. CCL4 and CSF2 were among the most upregulated genes in 
LAD2 cells and were selected for further analysis. qRT-PCR and ELISA analysis of LAD2 cells showed induction 
of CCL4 and CSF2 with LTE4 consistently matching or being the more potent of the 2 ligands (Fig. 1B). To verify 
whether this responsiveness to LTE4 is characteristic for other mast cells, another human mast cell line, LUVA, 
was analysed to compare responses to LTD4 and LTE4. Although in LUVA cells LTD4 regulated gene expression 
in a similarly potent way to LAD2 cells, LTE4 induced only very weak responses (Fig. 1C). As intracellular cal-
cium mobilisation is a secondary messenger signalling cue for classical leukotriene receptors, cysLT induced 
Figure 1. LTE4 is a potent agonist in LAD2 but not in LUVA cells. (A) LAD2 cells (n = 3) were stimulated 
with vehicle control, LTD4 and LTE4 and gene expression was analysed using microarrays. Hierarchical 
clustering of significantly (ANOVA, p < 0.05 LTD4 and LTE4 compared to control, False Discovery Rate = 0.1) 
regulated genes is presented as a heat map. (B) LAD2 and (C) LUVA cells were stimulated and CCL4 or CSF2 
gene expression were measured at mRNA and protein levels. Data expressed as mean ± SEM from 3 separate 
experiments. (D) LAD2, (E) LUVA and (F) HEK293T transfected with CYSLTR1 cells were stimulated 
with indicated concentrations of LTC4, LTD4 and LTE4 and calcium mobilisation was measured. Data from 
3 experiments run in triplicate, presented as mean ± SEM of baseline corrected peak intracellular calcium 
response. Relative fluorescence unit (RFU).
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calcium mobilisation was analysed in both cell lines. In LAD2 cells, all cysLTs induced a concentration-depend-
ent calcium mobilisation (Fig. 1D), with LTD4 and LTC4 showing similar potency (LTC4 EC50− 1.3 × 10−9 M, 
LTD4 EC50− 0.58 × 10−9 M) and LTE4 being the weakest of all 3 ligands but still inducing a robust response (LTE4 
EC50− 1.67 × 10−9 M). In contrast, LTD4 was the most potent ligand in LUVA cells (EC50− 2.8 × 10−9 M) followed 
by LTC4 (EC50− 1.7 × 10−8 M), while LTE4 induced very weak response (EC50-not determined)(Fig. 1E). Similar 
potencies of cysLTs as in LUVA cells were detected in HEK293T cells transfected with human CYSLTR1 (Fig. 1F) 
(LTC4 EC50− 1.12 × 10−8 M, LTD4 EC50− 0.9 × 10−9 M; LTE4 EC50− 8.32 × 10−8 M). Therefore LAD2 and LUVA 
cells represent two human mast cell lines that respond differently to LTE4 stimulation.
Comparison of GPCR gene expression profiles between LAD2 and LUVA cells. A previous study13 
has suggested that in LAD2 cells LTE4 signals through a novel, CysLT3 receptor, different from classical CysLT1 
and CysLT2. As our observations in LAD2 and LUVA cells indicated that a potential LTE4 receptor should be 
differentially expressed in LAD2 and LUVA cells, gene expression was compared between LAD2 and LUVA 
cells using microarray in order to identify the putative gene. A list of significantly differentially expressed genes 
(ANOVA p < 0.05; > 2 fold difference) was generated and GPCR genes were filtered using the IUPHAR GPCR 
database17. Among 27 GPCRs that differed significantly in expression between LAD2 and LUVA cells (Fig. 2A, 
supplementary Table 2), 10 GPCRs were considered orphan receptors (without known ligands)(GPR12, GPR37, 
GPR65, GPR85, GPR114, GPR137B, GPR174, MAS1L, MRGPRX2 and P2RY8). GPR65, MAS1L and MRGPRX2 
were the most differentially expressed orphan GPCRs (9.9, 32.4 and 70.2 fold difference between LAD2 and 
LUVA cells, respectively). To ascertain whether cysLTs, and LTE4 in particular, could mediate signalling through 
any of these receptors, plasmids encoding GPR65, MAS1L and MRGPRX2 were transiently transfected into 
HEK293T cells and calcium mobilisation was analysed upon stimulation with cysLTs (Fig. 2B). CYSLTR1 gene 
was among differentially expressed GPCRs and was used as a positive control for all experiments. No spe-
cific calcium responses were observed in any of the transfectants apart from cells transfected with CYSLTR1, 
which showed the predicted pattern of response to cysLTs. As co-transfections of GPCRs and Gα 16 have been 
Figure 2. Comparison of GPCR gene expression profiles between LAD2 and LUVA cells. (A) Microarray 
gene expression was compared in LAD2 and LUVA cells (n = 3) and hierarchical clustering of differentially 
expressed GPCRs (ANOVA, p < 0.05, > 2 fold difference) is presented as a heat map. Intracellular calcium 
mobilisation was analysed in HEK293T cells transiently transfected with the genes of interest (B) and co-
transfected with Gα 16 (C). Data expressed as percentage of peak calcium ionophore response, mean ± SEM 
from 3 experiments run in triplicate. LAD2 (D) and LUVA (E) cells were pre-treated with Montelukast 
(100 nmol/L) and HAMI3379 (1 μ mol/L) for 10 minutes, stimulated with LTD4 and LTE4 (both 100 nmol/L) 
and CCL4 mRNA expression or calcium mobilisation was measured. Data expressed as a fold difference in 
comparison to vehicle control or as baseline corrected peak calcium response. Mean ± SEM from 3 separate 
experiments. Relative fluorescence unit (RFU).
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reported previously to direct signal transduction to phospholipase C and calcium signalling18, target genes were 
co-expressed with human Gα 16 and responses to cysLTs measured using calcium mobilisation in order to analyse 
potential alternative GPCR signalling pathway. Similarly, no response was observed in any of our overexpression 
models apart from CYSLTR1 transfected cells (Fig. 2C). Thus CysLT1 was the receptor that was differentially 
expressed in LAD2 and LUVA cells (4.3 fold difference) and responded to cysLTs.
CysLT1 is required for LTE4 induced signalling in LAD2 cells. To determine whether CysLT1 could 
be involved in LTE4 signal transduction, LAD2 and LUVA cells were pretreated with selective CysLT1 and 
CysLT2 antagonists, Montelukast and HAMI3379, respectively. Antagonists’ selectivity was previously verified 
in HEK293T cell transfection models (supplementary Figure 1). qRT-PCR analysis of CCL4 gene expression 
in LAD2 cells showed that both LTD4 and LTE4 induced responses were fully inhibited by Montelukast while 
HAMI3379 had no effect (Fig. 2D). In LUVA cells, LTD4 signalling was again fully inhibited by Montelukast but 
not by HAMI3379 (Fig. 2E). Analysis of calcium mobilisation in these cells showed a very similar picture, with 
Montelukast fully inhibiting LTE4 responses in LAD2 as well as LTD4 responses in LAD2 and LUVA cells while 
HAMI3379 had no effect (Fig. 2D,E). To verify whether the potent LTE4 induced, Montelukast sensitive, response 
in LAD2 cells was attributable specifically to CysLT1 signalling and not via another Montelukast sensitive recep-
tor, stable CYSLTR1 receptor knockdown was generated in LAD2 cells using shRNA. Four shRNA targeting 
different regions of CYSLTR1 were transduced into separate LAD2 cell populations using lentiviral particles. 
qRT-PCR analysis of CYSLTR1 revealed shRNA “475” to significantly knock down CYSLTR1, without affect-
ing CYSLTR2 mRNA expression (supplementary Figure 2). Knocking down of CYSLTR1 substantially inhibited 
intracellular calcium responses to LTD4 and LTE4 (Fig. 3A,B), confirming a functional decrease in CysLT1 expres-
sion. CCL4 and CSF2 mRNA and protein expression upon LTD4 and LTE4 stimulation were almost completely 
abrogated in CysLT1 knocked down LAD2 cells (Fig. 3C,D and supplementary Figure 3) identifying CysLT1 as a 
receptor responsible for LTE4 induced signalling in LAD2 cells.
Overexpression of CysLT1 in LUVA cells does not determine LTE4 responses. Our GPCR expres-
sion profiles identified CYSLTR1 as more highly expressed in LAD2 than in LUVA cells. To test the hypothe-
sis that the expression level of CYSLTR1 is relevant for mast cell responsiveness to LTE4, CYSLTR1 was stably 
overexpressed in LUVA cells using lentiviral transduction and positive clones were selected using puromycin. 
Figure 3. CysLT1 is required for LTE4 induced signalling in LAD2 cells. Calcium mobilisation responses 
to LTD4 (A) and LTE4 (B) in Empty control (Ctrl) and CYSLTR1 knocked down (CYSLTR1 KD) LAD2 cells. 
Baseline corrected peak calcium responses from 3 experiments run in triplicate presented as mean ± SEM. 
(C) Control and CYSLTR1 knocked down LAD2 cells were stimulated with vehicle control, LTD4 or LTE4 for 
2 (mRNA) (C) or 6 hours (protein) (D) before analysis. Data expressed as fold difference in comparison to 
vehicle control for CCL4 mRNA and as CCL4 supernatant concentrations. Mean ± SEM from 3–5 experiments, 
relative fluorescence unit (RFU). (E) LUVA cells were stably transduced with empty (LUVA-empty) or 
CYSLTR1 overexpression (LUVA-CYSLTR1) vectors and relative CYSLTR1 mRNA expression was measured 
and compared to LAD2 cells. Mean ± SEM, n = 6. (F) Calcium mobilisation response to a range of LTE4 
concentrations was evaluated in empty control and CYSLTR1 transduced LUVA cells. Mean ± SEM of baseline 
corrected peak calcium responses, n = 9. Control empty vector and CYSLTR1 transduced LUVA cells were 
stimulated as indicated before CCL4 mRNA (G) or protein (H) expression was measured. Mean ± SEM of 3 
separate experiments.
www.nature.com/scientificreports/
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qRT-PCR confirmed a 3-fold increase in CYSLTR1 expression in the transduced population, a level similar 
to LAD2 cells (Fig. 3E). Functional CYSLTR1 overexpression was confirmed using calcium assay and showed 
potent concentration-dependent increase in LTE4 induced calcium responses (Fig. 3F), again similar to responses 
observed in LAD2 cells. Stimulation of LUVA cells overexpressing CysLT1 and control empty vector-transduced 
cells with either LTD4 or LTE4 revealed no significant differences in CCL4 mRNA or protein induction between 
both cell lines (Fig. 3G,H), showing that the expression level of CysLT1 does not solely determine LTE4 induced 
gene regulation, even though it allows for enhanced calcium mobilisation in response to LTE4.
Comparison of CYSLTR1 gene sequence between LAD2 and LUVA cells. As genetic variations 
in the CYSLTR1 gene between LAD2 and LUVA cells could account for such differential responses to LTE4, 
promoter and coding regions of CYSLTR1 in both cell types were sequenced. DNA was extracted and CYSLTR1 
promoter fragment containing 4 single nucleotide polymorphisms (SNPs)(rs321029, rs2637204, rs2806489, 
rs7066737) as well as the entire coding region were PCR amplified and sequenced. BLAST analysis of DNA 
sequences from LAD2 and LUVA cells revealed no differences between cell lines and showed that both cell lines 
share the same promoter homozygous haplotype, “CAAC” for 4 SNPs studied, respectively and homozygous T 
allele for rs320995 coding synonymous SNP. Human CYSLTR1 gene is localized to chromosome X thus lack of 
heterozygosity at the locus was consistent with the fact that both cell lines were derived from male donors.
CysLT-activated CysLT1 signals through Gαq, calcium and Erk for gene regulation. In order to 
compare CysLT1 mediated signalling in LAD2 and LUVA, both cell types were pre-incubated with several signal-
ling pathway inhibitors and gene expression was measured in response to LTD4 and LTE4 (Fig. 4A,B). LTD4- and 
Figure 4. LTE4 induces sustained signalling in LAD2 cells. LAD2 (A) and LUVA (B) cells were pre-treated 
with selected inhibitors and stimulated with LTD4 or LTE4. Data from 3 separate experiments shown as % of 
LTD4-induced CCL4 mRNA expression (mean ± SEM), *p < 0.05, **p < 0.001, ANOVA with Bonferroni post 
test compared to LTD4 or LTE4. (C) LAD2 and LUVA cells were stimulated for time indicated with vehicle 
control (Ctrl), LTD4 or LTE4 (both 100 nmol/L) and phosphorylated Erk and total Erk expression measured 
using specific antibodies. Results from a representative experiment of 3 performed. Calcium mobilisation traces 
of LAD2, LUVA or LUVA-CYSLTR1 cells stimulated as indicated with LTD4 or LTE4 (100 nmol/L) once (D) or 
twice (E). Representative of 3 separate experiments, relative fluorescence unit (RFU). Black arrows indicate start 
of stimulation. (F) LAD2 and LUVA cells were exposed for either 5 minutes or 2 hours to vehicle control, LTD4 
or LTE4 (both 100 nmol/L) and CCL4 mRNA measured by qRT-PCR after 2 hours incubation. Mean ± SEM 
data from 3 experiments shown as a fold change in comparison to controls. *p < 0.05, 2-way ANOVA 
comparison between 5 min LTD4 and LTE4 stimulations.
www.nature.com/scientificreports/
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LTE4-induced CCL4 mRNA expression was potently inhibited by U0126 (MEK/Erk pathway inhibitor), intra-
cellular (BAPTA-AM) and extracellular (EDTA) calcium chelators but was not modified by pertussis toxin or 
GW9662 and T0070907 (PPAR-γ inhibitors), suggesting that in both cell lines CysLT1 couples to Gα q, requires 
intracellular and extracellular calcium and Erk activation for regulation of gene expression.
LTE4 activates prolonged signalling in LAD2 cells. To further analyse the agonistic activity of LTE4, 
time course experiments of Erk phosphorylation were conducted and analysed by Western blotting (Fig. 4C). In 
LAD2 cells stimulated with LTD4, Erk phosphorylation peaked at 7 minutes with a gradual decrease until 60 min-
utes. LTE4 induced a peak of Erk phosphorylation later but with a more sustained phosphorylation, still being 
detectable after 60 minutes. In LUVA cells the time point of highest Erk phosphorylation was similar to LAD2 
cells but LTE4-induced Erk phosphorylation was shorter than in LAD2 cells. Thus sustained Erk phosphorylation 
induced by LTE4 in LAD2 but not in LUVA cells underlies an important difference in CysLT1-mediated responses 
between the cell lines.
We next compared calcium mobilisation kinetics in LAD2 cells; although LTD4 induced a higher peak 
response than LTE4, the intracellular calcium levels decreased at a higher rate after LTD4 stimulation while LTE4 
induced a long lasting plateau phase (Fig. 4D). The sustained calcium signalling in response to LTE4 was not 
observed in LUVA cells or in LUVA cells overexpressing CysLT1 (Fig. 4D).
As GPCR signalling is regulated through receptor desensitization, cross desensitization experiments with cys-
LTs were performed (Fig. 4E). Prior stimulation with either LTC4 or LTD4 completely abrogated calcium response 
to LTD4 in LAD2 and LUVA cells, suggesting that both LTC4 and LTD4 can fully desensitize CysLT1 in both cell 
lines. However, prior stimulation with LTE4 caused only partial inhibition of the calcium response to LTD4 in 
LAD2 and LUVA cells, showing partial agonistic/desensitizing activity of LTE4 but no difference between the cell 
lines in LTE4 mediated signalling. The sustained increased level of calcium in LAD2 but not in LUVA cells after 
LTE4 stimulation was again the main difference observed between the cell lines in these experiments.
To analyse whether prolonged calcium/Erk signalling induced by LTE4 in LAD2 cells affects gene expression, 
CCL4 mRNA expression was analysed in LAD2 and LUVA cells after short (5 minutes) and long (2 hours) term 
exposure to LTD4 and LTE4, respectively. In LAD2 cells, 2 hour exposure to LTE4 and LTD4, caused similar upreg-
ulation of CCL4 mRNA expression (Fig. 4F). Stimulation of LAD2 cells with LTE4 for only 5 minutes failed to 
induce potent CCL4 expression with mRNA levels being significantly lower than that induced by LTD4. In LUVA 
cells, no difference could be observed between different exposure times.
Discussion
This study identifies LTE4 as a fully functional agonist activating human CysLT1 for regulation of gene expression 
in LAD2 cells although only weak, partial agonism of LTE4 signalling could be detected in LUVA cells. Our data 
suggest that increased expression of CysLT1 and induction of prolonged intracellular signalling are required for 
LTE4 functional agonism. Ever since the elucidation and cloning of human CysLT1 and CysLT2, LTE4 has been 
considered as a final, non-active leukotriene metabolite due to its weak efficacy in recombinant systems and 
poor binding affinities compared to LTC4 and LTD46. However, it was LTE4 that was shown to be the most potent 
cysLT in inducing inflammatory and contractile responses in asthmatic subjects. Our observation that LTE4 can 
induce full agonistic activity through CysLT1 could be of relevance for explaining this discrepancy between potent 
in vivo activity of LTE4 observed in asthmatic patients and weak in vitro potency for classical cysLT receptors. 
Early studies analysing the effects of cysLTs in vivo revealed a disproportionate augmentation in relative responses 
to LTE4 inhalation in asthmatic patients when compared to healthy individuals10. LTE4 responsiveness was 
increased more than 200 fold in asthmatics while responses to LTC4 and LTD4 were increased 6 and 9 fold respec-
tively. More recent clinical studies suggest that CysLT1 is more highly expressed in asthmatic airways compared to 
healthy individuals19, with further increase observed in asthma exacerbations and in a sub-phenotype of asthma, 
patients with aspirin-exacerbated respiratory disease (AERD)20,21. This increased CysLT1 expression observed in 
AERD patients was significantly decreased following successful aspirin desensitisation, a procedure associated 
also with a significant reduction in sensitivity to inhaled LTE420. We found similar disproportionate augmenta-
tion in LTE4-induced responses when comparing LAD2 and LUVA cells, a model of relatively high versus low 
CysLT1 expression. LTC4 and LTD4 were 2–3 times more potent at inducing calcium mobilisation in LAD2 cells 
compared to LUVA while LTE4 showed nearly 60-fold difference. Such potent responses to cysLTs, including LTE4 
have been recently described in other human primary cells expressing high levels of CysLT1, T helper type 2 (Th2) 
lymphocytes22,23 and group 2 innate lymphoid cells (ILC2)24 supporting further our observation.
Prolonged intracellular signalling was identified as another potential contributing factor for the potency of 
LTE4 responses. The sustained increase in intracellular calcium and Erk phosphorylation upon LTE4 stimulation 
were observed in LAD2 but not in LUVA cells, suggesting that prolonged signalling could be critical for transcrip-
tional regulation. LTE4, in contrast to LTC4 and LTD4, shows only partial activity and does not desensitise CysLT1 
responses, a feature that can contribute to prolonged signalling in response to LTE4 in LAD2 cells. In fact, in 
experiments with short term exposure to agonists LTE4 showed only weak, partial agonist activity in comparison 
to LTD4, confirming important role of prolonged signalling in LTE4 induced responses. Overexpression of CysLT1 
in LUVA did not restore sustained intracellular calcium and full agonism even though it increased peak calcium 
response to LTE4, suggesting that additional unidentified signalling molecules expressed in LAD2 cells but not in 
LUVA, are also required for full functional agonism of LTE4.
Mouse models provide strong evidence that CysLT1 and CysLT2 are not the only cysLT receptors as germline 
deletion did not diminish leukotriene-mediated inflammation11,14,25. Our data presented here provide an expla-
nation for potent LTE4 activity observed in humans but do not rule out the possibility of another cysLT receptor. 
Our study shows for the first time that CysLT1 expression is critically important for responsiveness to LTE4 within 
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a human cell system. This could potentially be relevant for human cell types other than mast cells and could thus 
have important implications for diagnostics and targeted treatment of specific phenotypes of asthma.
Materials and Methods
Reagents. Leukotrienes (LTC4, LTD4 and LTE4), Montelukast, MK-571, HAMI3379, U-0126, GW9662, 
T0070907 (all Cayman Chemical), EDTA (Ambion), BAPTA-AM, Pertussis Toxin, Calcium ionophore (A23187), 
(all Sigma-Aldrich) were obtained from the manufacturers.
Cell Culture. HEK293T cells were cultured in DMEM medium supplemented with 2 mmol/L glutamine, 10% 
fetal bovine serum and Penicillin/Streptomycin (50 units/ml) (all Life Technologies) in a humidified 5% CO2 
37 oC incubator. LAD2 cells (a kind gift from Dr. Arnold Kirshenbaum, NIAID, NIH, USA26) and LUVA cells 
(a kind gift from Dr. John Steinke, University of Virginia, USA27) were cultured in StemPro-34 medium sup-
plemented with with L-glutamine (2 mmol/L), Pen/Strep (50 IU/ml) and with or without stem cell factor (SCF) 
(100 ng/ml) (all Life Technologies), respectively. Cells were hemidepleted weekly with fresh medium.
Transient transfections. HEK293T cells cultured to above 60% confluence were transiently transfected as 
described previously4,15 with a mixture of Lipofectamine 2000 (Life Technologies) and the following plasmids 
as indicated: pcDNA3.1-empty, pcDNA3.1-human CYSLTR1, pcDNA3.1-human CYSLTR2, pcDNA3.1-human 
GPR65, pcDNA3.1-human GNA15 (Gα 16) (all the Missouri S&T cDNA Resource Center, Rolla, Mo) and 
pCMV6-Kan/Neo- human MAS1L and human MRGPRX2 (Origene Technologies) in serum-free medium 
(Opti-MEM, Life Technologies) according to manufacturer’s protocol. After incubation the transfection medium 
was removed and HEK293T cells were cultured for 36 hours before calcium mobilisation was assayed in response 
to stimulation with calcium ionophore (1μ mol/L), LTC4, LTD4 and LTE4 (all 100 nmol/L).
Short hairpin RNA (shRNA) knockdown. For stable gene silencing shRNA constructs targeting different 
regions of human CYSLTR1 (clone ID: V3LHS_305475, V3LHS_305478, V2LHS_90946 and V2LHS_90947) 
were purchased from ThermoScientific and used to generate lentiviral particles with the lentiviral packaging sys-
tem (psPAX2, pMD2.G and PEG-it™ precipitation)(System Biosciences) according to manufacturer’s protocol. 
LAD2 cells were transduced with viral particles for 24 hours and positive cells selected using Puromycin (2μ g/ml)
(Life Technologies). Efficiency of transduction was assessed by analysing GFP expression using flow cytometry.
CYSLTR1 overexpression. CYSLTR1 gene was amplified from the pcDNA3.1-CYSLTR1 construct 
(UMR cDNA Resource Center) with primers containing restriction enzyme sites for NheI and BamHI 
(5′ -AGGTGCTAGCATGGATGAAACAGGAAATT and 5′ -GCGGGGATCCCTATACTTTACATATTTC) and 
cloned into lentiviral vector pCDH (System Biosciences) encoding GFP and puromycin resistance under the EF1 
promoter and a multiple cloning site under the CMV promoter. Viral particles were generated using lentiviral 
packaging system (System Biosciences). LUVA cells were transduced, selected with puromycin (2μ g/ml) and 
transduction efficiency was evaluated by GFP expression using flow cytometry.
DNA sequencing. Total DNA was extracted using DNeasy Tissue kit (Qiagen) and fragments 
of CYSLTR1 gene were amplified using Platinum Taq Polymerase High Fidelity (Invitrogen) follow-
ing manufacturer’s protocol and primers: CYSLTR1 promoter 5′-AACTGGAGACTTGCAGGTTGCG, 
5′-AACATCAAAGTGCTGCCCCAGG; CYSLTR1 coding region 5′-TCAATGCCTCACTACTATTGCTTG, 
5′-TTGGTTTGGACTGGAAATGGG and sequenced by Source Bioscience Sanger service using custom designed 
primers: CYSLTR1 promoter 5′-TAAGATGGGAAGCAGGGACG, 5′-GGCTTCAATCAGCACATACC; 
CYSLTR1 coding region 5′-ATACCAAGTGCTTTGAGCC, 5′-GCATTTGGCTCTTTGGTG and 
5′-GTTTGATTGTCTTGTGGGG.
Calcium mobilisation assay. Calcium mobilisation assays were conducted using FLIPR calcium 4 assay 
kit (Molecular Devices) as described previously4,28. Cells (1.5 × 105/well) were plated into poly-L-lysine coated 
96 well plates in RPMI 1640 supplemented with 10 mmol/L HEPES, incubated for 1 hour with FLIPR loading 
buffer prior to addition of ligand and fluorescent intensity was measured at 37 °C using a Flexstation 3 (Molecular 
Devices). Controls included medium control with ethanol for leukotriene stimulations. Results were analysed 
with SoftMax Pro Software (Molecular Devices).
Real time PCR. LAD2 and LUVA cells were stimulated for 2 hours in the presence of L-cysteine (3 mmol/L) 
with LTD4 and LTE4 (both 100 nmol/L) and vehicle control. In some experiments as indicated cells were pre-
treated with U0126 (1μ mol/L; 30 min), BAPTA-AM (30μ mol/L; 30 min), EDTA (2.5 mmol/L; 5 min), pertussis 
toxin (PTX)(100 ng/ml; overnight), GW9662 (10μ mol/L; 30 min) or T0070907 (1μ mol/L; 30 min). Total cellular 
RNA was isolated using the miRNeasy mini kit (Qiagen), DNAase treated (Ambion) and reverse transcribed 
using RevertAid M-MuLV (Fermentas). Expression of mRNA encoding selected genes was measured using 
real time PCR on an ABI Prism 7900 Sequence Detection System (Applied Biosystems). Commercially avail-
able primer probe sets: 18S rRNA - 4319413E (Applied Biosystems) and individually designed assays using the 
Universal Probe Library (UPL) (Roche): CYSLTR1- probe 71, primers 5′-GGAGAGGGTCAAAGCAACAA, 
5′-TGCAGAAGTCCGTGGTCATA; CYSLTR2- probe 21, primers 5′-TGATGTGACACTGCCGTTCT, 
5′-TCATGGCTTCCTCAATAATGC; CCL4- probe 20, primers 5′-CAGCACAGACTTGCTTGCTT, 
5′-CTTCCTCGCAACTTTGTGGT; CSF2- probe 1,  primers 5′-GCCCTTGAGCTTGGTGAG, 
5′-TCTCAGAAATGTTTGACCTCC were used. All primers/probes were tested for optimal efficiency of ampli-
fication. Relative gene expression was normalized to 18S rRNA. Data were analysed using SDS2.1 software 
(Applied Biosystems).
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Microarray Analysis. Total cellular RNA was isolated using the miRNeasy mini kit (Qiagen), DNase treated 
(Ambion), quality analysed on an Agilent 2100 Bioanalyzer (Agilent Technologies) and further processed with 
the Ambion WT Expression Kit (Applied Biosystems) according to the manufacturers’ instructions29. cRNA was 
fragmented, labelled, and hybridised to the Affymetrix Human Gene 1.0 ST Arrays using the Gene Chip WT 
Terminal Labeling and Hybridization Kit (Affymetrix). GeneChip fluidics station 450 (Affymetrix) was used 
for processing of the arrays and fluorescent signals were detected with the GeneChip scanner 3000. Images were 
analysed with the GeneChip operating software (Affymetrix). Further analysis was performed with the Partek 
Genomics Suite (Partek). RMA processing and quantile normalization was applied, and after Median Polish and 
gene level probeset summarization, differentially expressed genes were identified using ANOVA. Data were sub-
mitted to Gene Expression Omnibus database (accession number GSE75603).
Western Blot Analysis. Total protein lysates were prepared using lysis buffer containing 1 mM protease 
inhibitor cocktail (Roche), 25 μ g proteins loaded onto a 10% Bis-Tris NuPage gel (Invitrogen) and transferred 
onto a nitrocellulose membrane (Invitrogen). The membrane was incubated with primary antibodies against 
phospho-p44/42 MAPK and p44/p42 MAPK (Extracellular-signal-regulated kinase (ERK))(Cell Signaling) over-
night at 4 °C, followed by secondary, horseradish peroxidase-conjugated antibody (goat anti rabbit IgG (Southern 
Biotech). Blots were developed using ECL plus Detection Reagent (GE Healthcare) and visualized on a Chemidoc 
MP System (BioRad). Data were analysed using Image Lab 4.1 software (BioRad).
ELISA. LAD2 and LUVA cells were stimulated for 6 hours in the presence of L-cysteine (3 mmol/L) with LTD4 
and LTE4 (both 100 nmol/L) and vehicle control. CCL4 and CSF2 concentrations were measured in supernatants 
using human CCL4 (MIP-1β ) and CSF2 (GM-CSF) duo set kits (R&D Systems, UK) following manufacturer’s 
protocol.
Statistical analysis. Data were analysed by means of one- or two- way ANOVA using GraphPad Prism 
software (GraphPad). Differences were considered significant at a p-value of less than 0.05.
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